ストックスクリーナーアプリを入手
4.57
12.45%
-0.65
アフターアワーズ：
4.57
Verve Therapeutics Inc (VERV) 最新ニュース
Swiss National Bank Purchases 18,000 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Did Verve Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– VERV - ACCESS Newswire
Investigation announced for Long-Term Investors in shares - openPR.com
Pixalate Releases Q4 2024 United Kingdom Connected TV (CTV) Ad Supply Chain Trends Report: Samsung Smart TV Leads in Device Market Share (30%); Ad Fraud (IVT) Rate Hits 16% - GlobeNewswire Inc.
Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts - Seeking Alpha
Verve Therapeutics Announces Clearance of Investigational - GlobeNewswire
Verve Therapeutics Says US FDA Clears Verve-102 IND Application for Premature Coronary Artery Disease - MarketScreener
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose - The Manila Times
Game-Changing FDA Green Light: Verve's One-Time Gene Therapy Takes On High Cholesterol - Stock Titan
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by Arizona State Retirement System - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by US Bancorp DE - Defense World
Verve Therapeutics Inc (VERV): Significant Improvements, Worth Considering - Stocks Register
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Rhumbline Advisers - Defense World
IFP Advisors Inc Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
(VERV) Technical Data - Stock Traders Daily
Verve Therapeutics (NASDAQ:VERV) Shares Gap Down After Analyst Downgrade - Defense World
Verve Therapeutics (NASDAQ:VERV) Price Target Cut to $15.00 by Analysts at Royal Bank of Canada - Defense World
Verve Therapeutics price target lowered to $15 from $17 at RBC Capital - TipRanks
RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk - Marketscreener.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
How Verve Therapeutics Is Attracting Talent: New Equity Compensation Package Details - StockTitan
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Analysts Set Expectations for VERV Q1 Earnings - Defense World
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
HC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) Stock - Defense World
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright lifts VERVE Therapeutics price target to $15 By Investing.com - Investing.com Canada
Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity - TipRanks
Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - News & Insights
Verve TherapeuticsKey Data Catalysts, Major Share Price Volatility In Play In Q2 - Seeking Alpha
Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position - TipRanks
Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts - TipRanks
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Verve Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance UK
Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Verve Therapeutics: Q4 Earnings Snapshot - Houston Chronicle
Verve Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Verve Therapeutics reports Q4 EPS (58c), consensus (67c) - TipRanks
Vertex ends gene editing research pact with Verve - BioPharma Dive
Verve Therapeutics, Inc. SEC 10-K Report - TradingView
Verve Therapeutics: Q4 Earnings Snapshot -February 27, 2025 at 07:33 am EST - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Can Verve's Gene Editing Trials Deliver? Key PCSK9 Data Coming in 2025 With $524M War Chest - StockTitan
VERV STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVERV - ACCESS Newswire
How To Trade (VERV) - news.stocktradersdaily.com
William Blair Reaffirms Outperform Rating for Verve Therapeutics (NASDAQ:VERV) - Defense World
Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Tuesday - Defense World
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):